Smith L H, Teng N N
Department of Gynecology and Obstetrics, Stanford University School of Medicine, California 94305.
Cancer. 1987 Oct 15;60(8 Suppl):2068-74. doi: 10.1002/1097-0142(19901015)60:8+<2068::aid-cncr2820601520>3.0.co;2-a.
The advances of both murine and human monoclonal antibody (MoAb) technology have allowed the development of several antibodies against gynecologic tumors. The goals are to produce effective and specific reagents for both immunodiagnosis and therapy. However, despite an extensive research effort, a clear demonstration of specific cancer-associated antigens in gynecologic malignancies, or of specific immune responses to such antigens has been elusive. Currently, most antibodies found are cross reactive with either oncofetal antigens or some normal adult tissues. Clinical usefulness of these MoAbs as a screening test in radioimaging or in immunotherapy remains to be proven. However, the use of MoAb technology in defined antigens/tumor markers such as beta-human chorionic gonadotropin, and alpha fetal proteins has provided convenient, reproducible and highly specific reagents. More recently, promising antibodies have been shown to detect tumor antigens in serum of patients with ovarian cancer.
小鼠和人单克隆抗体（MoAb）技术的进展使得针对妇科肿瘤的几种抗体得以研发。目标是生产用于免疫诊断和治疗的有效且特异性试剂。然而，尽管进行了广泛的研究工作，但在妇科恶性肿瘤中明确证明特定的癌症相关抗原，或针对此类抗原的特异性免疫反应一直难以实现。目前，发现的大多数抗体与癌胚抗原或某些正常成人组织存在交叉反应。这些单克隆抗体作为放射成像或免疫治疗中的筛查试验的临床实用性仍有待证明。然而，将单克隆抗体技术应用于特定抗原/肿瘤标志物，如β-人绒毛膜促性腺激素和甲胎蛋白，已提供了方便、可重复且高度特异性的试剂。最近，有前景的抗体已被证明可检测卵巢癌患者血清中的肿瘤抗原。
